Trotana Therapeutics is focused on discovering and developing therapeutics that target RNA binding proteins to address unmet medical needs across various indications. By leveraging expertise in this novel field, the company aims to create effective treatments for conditions that currently lack viable options.
Funding
$18M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many diseases lack effective treatments due to the difficulty in targeting the underlying biological mechanisms with traditional drug development approaches. Specifically, targeting RNA binding proteins (RBPs), which play a crucial role in regulating RNA and protein production, has been largely unexplored, leaving a significant gap in therapeutic options for various conditions.
Solution
Trotana Therapeutics is developing therapeutics that target RNA binding proteins (RBPs) to address unmet medical needs across a variety of indications. By focusing on RBPs, Trotana aims to modulate RNA processing and protein expression, offering a novel approach to treating diseases that are currently difficult to address with conventional therapies. The company leverages expertise in RBP biology to discover and develop medicines that can effectively target these proteins and modulate their function. This approach has the potential to create new treatment options for conditions where existing therapies are inadequate or non-existent.
Target Audience
The primary target audience includes patients with diseases that currently lack viable treatment options, as well as pharmaceutical companies seeking innovative approaches to drug development.
Features
- Focus on discovering and developing therapeutics targeting RNA binding proteins (RBPs).
- Aims to modulate RNA processing and protein expression.
- Novel approach to treating diseases that are difficult to address with conventional therapies.